Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Operating Leases: 2019-2025

Historic Operating Leases for Ironwood Pharmaceuticals (IRWD) over the last 6 years, with Sep 2025 value amounting to $10.5 million.

  • Ironwood Pharmaceuticals' Operating Leases fell 18.51% to $10.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year decrease of 18.51%. This contributed to the annual value of $12.3 million for FY2024, which is 15.40% down from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Operating Leases is $10.5 million, which was down 5.57% from $11.1 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Operating Leases' 5-year high stood at $19.9 million during Q1 2021, with a 5-year trough of $10.5 million in Q3 2025.
  • For the 3-year period, Ironwood Pharmaceuticals' Operating Leases averaged around $13.4 million, with its median value being $13.5 million (2024).
  • Data for Ironwood Pharmaceuticals' Operating Leases shows a maximum YoY dropped of 18.51% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Operating Leases stood at $18.5 million in 2021, then declined by 10.20% to $16.6 million in 2022, then dropped by 12.39% to $14.5 million in 2023, then fell by 15.40% to $12.3 million in 2024, then dropped by 18.51% to $10.5 million in 2025.
  • Its Operating Leases stands at $10.5 million for Q3 2025, versus $11.1 million for Q2 2025 and $11.7 million for Q1 2025.